Use of MVA to treat prostate cancer
US7867483B2 · kind B2 · utility
11Cited by
6References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 16, 2008 |
| Grant date | Jan 11, 2011 |
| Priority date | — |
| Expiry date | Oct 28, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2830/60
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to compositions, kits, and methods for cancer prophylaxis and therapy using recombinant MVA viruses encoding tumor-associated antigens, such as PSA and PAP. The recombinant MVA viruses can induce B- and T-cell responses. The recombinant MVA viruses can be administered prior to, at the same time as, or after a taxane.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.